Clinical trials are vital to medical advances and better patient care
Only with adequate participation can these trials return trustworthy data and move personalized healthcare forward. But structural and clinical barriers make trial participation unachievable for more than three out of four cancer patients.1
One significant obstacle is physicians’ lack of resources to identify trials for their patients and advocate for enrollment. Doctors may also worry that a trial may interfere with the physician-patient relationship or the patient’s commitment to the referring institution.
Patient enrollment is one of the biggest causes of drug development delays2
Low enrollment of cancer patients in clinical trials is well documented. The causes are many, including:
- Limited human resources and time for cancer care teams to research clinical trials
- Difficulty for clinicians to keep up with available trials
- Strict inclusion/exclusion criteria
- The lack of patient insurance coverage for clinical trials
But technology and integrated clinical decision support can simplify the identification of trials for patients based on personal preferences (e.g., location, trial duration/time commitment, costs and/or reimbursements, etc.), tumor information, trial eligibility and ineligibility criteria, and more.